Figure 1
Age-dependent prevalence of viral seroprevalence and genetic risk factors. (A) Hepatitis E virus seroprevalence in untreated AIH and non-AIH liver diseases (patient numbers for all serological tests are outlined in Table 1 and Suppl. Tables 1–3). Significant results from the age-dependent Fisher’s exact tests are depicted in the graphs. The dotted lines represent 95% confidence intervals (CIs). (B) Prevalence of previous hepatitis A infections in untreated AIH patients, in the German population from a health monitoring study (DEGS1)43 and in a local pediatric control either without liver diseases or with non-AIH liver diseases. The dotted lines represent CIs. (C) Seroprevalence in untreated adult AIH patients and in the adult German population according to two health monitoring studies (BSG98, DEGS1)14. The error bars represent the CIs. (D) Seroprevalence of anti-HSV, anti-VZV, anti-CMV, anti-EBV, and anti-HHV6 in patients with untreated AIH. (E) Prevalence of anti-parvovirus B19 (PVB19) antibodies in patients with untreated pediatric AIH and in a local pediatric control (Table 1). (F) Prevalence of HLA DRB1 risk alleles in AIH patients without overlap syndromes (0–17 years: n = 97; 18–39 years: n = 84; 40–59 years: n = 85; ≥60 years: n = 48) based on our previous studies26,27. Only p-values of the comparison of 03:01 against 04:01 are depicted (n.s. = not significant).
